Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases.

Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, Wang PH, LeeHealey CJ, S Andrews B, Sankaranarayanan A, Homerick D, Roeck WW, Tehranzadeh J, Stanhope KL, Zimin P, Havel PJ, Griffey S, Knaus HG, Nepom GT, Gutman GA, Calabresi PA, Chandy KG.

Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17414-9. Epub 2006 Nov 6.

2.

Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.

Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, Crossley G, Khaytin I, Calabresi PA, Chen CY, Gutman GA, Chandy KG.

Mol Pharmacol. 2005 Apr;67(4):1369-81. Epub 2005 Jan 21.

3.

Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases.

Chhabra S, Chang SC, Nguyen HM, Huq R, Tanner MR, Londono LM, Estrada R, Dhawan V, Chauhan S, Upadhyay SK, Gindin M, Hotez PJ, Valenzuela JG, Mohanty B, Swarbrick JD, Wulff H, Iadonato SP, Gutman GA, Beeton C, Pennington MW, Norton RS, Chandy KG.

FASEB J. 2014 Sep;28(9):3952-64. doi: 10.1096/fj.14-251967. Epub 2014 Jun 2.

4.

Kv1.3 potassium channels as a therapeutic target in multiple sclerosis.

Rangaraju S, Chi V, Pennington MW, Chandy KG.

Expert Opin Ther Targets. 2009 Aug;13(8):909-24. doi: 10.1517/14728220903018957. Review.

PMID:
19538097
5.

The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS.

Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, Beeton C, Chandy KG.

J Clin Invest. 2003 Jun;111(11):1703-13. Erratum in: J Clin Invest. 2003 Jul;112(2):298.

6.

Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.

Tarcha EJ, Chi V, Muñoz-Elías EJ, Bailey D, Londono LM, Upadhyay SK, Norton K, Banks A, Tjong I, Nguyen H, Hu X, Ruppert GW, Boley SE, Slauter R, Sams J, Knapp B, Kentala D, Hansen Z, Pennington MW, Beeton C, Chandy KG, Iadonato SP.

J Pharmacol Exp Ther. 2012 Sep;342(3):642-53. doi: 10.1124/jpet.112.191890. Epub 2012 May 25.

7.

Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma.

Koshy S, Huq R, Tanner MR, Atik MA, Porter PC, Khan FS, Pennington MW, Hanania NA, Corry DB, Beeton C.

J Biol Chem. 2014 May 2;289(18):12623-32. doi: 10.1074/jbc.M113.517037. Epub 2014 Mar 18.

8.

Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block.

Matheu MP, Beeton C, Garcia A, Chi V, Rangaraju S, Safrina O, Monaghan K, Uemura MI, Li D, Pal S, de la Maza LM, Monuki E, Flügel A, Pennington MW, Parker I, Chandy KG, Cahalan MD.

Immunity. 2008 Oct 17;29(4):602-14. doi: 10.1016/j.immuni.2008.07.015. Epub 2008 Oct 2.

9.

Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases.

Beeton C, Pennington MW, Norton RS.

Inflamm Allergy Drug Targets. 2011 Oct;10(5):313-21. Review.

10.

Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes.

Hu L, Pennington M, Jiang Q, Whartenby KA, Calabresi PA.

J Immunol. 2007 Oct 1;179(7):4563-70.

11.

Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes.

Pennington MW, Beeton C, Galea CA, Smith BJ, Chi V, Monaghan KP, Garcia A, Rangaraju S, Giuffrida A, Plank D, Crossley G, Nugent D, Khaytin I, Lefievre Y, Peshenko I, Dixon C, Chauhan S, Orzel A, Inoue T, Hu X, Moore RV, Norton RS, Chandy KG.

Mol Pharmacol. 2009 Apr;75(4):762-73. doi: 10.1124/mol.108.052704. Epub 2009 Jan 2.

12.

Curcumin serves as a human kv1.3 blocker to inhibit effector memory T lymphocyte activities.

Lian YT, Yang XF, Wang ZH, Yang Y, Yang Y, Shu YW, Cheng LX, Liu K.

Phytother Res. 2013 Sep;27(9):1321-7. doi: 10.1002/ptr.4863. Epub 2012 Nov 7.

PMID:
23132777
13.

Blockade of Kv1.3 potassium channels inhibits differentiation and granzyme B secretion of human CD8+ T effector memory lymphocytes.

Hu L, Wang T, Gocke AR, Nath A, Zhang H, Margolick JB, Whartenby KA, Calabresi PA.

PLoS One. 2013;8(1):e54267. doi: 10.1371/journal.pone.0054267. Epub 2013 Jan 30.

14.

The effects of Kv1.3 and IKCa1 potassium channel inhibition on calcium influx of human peripheral T lymphocytes in rheumatoid arthritis.

Toldi G, Bajnok A, Dobi D, Kaposi A, Kovács L, Vásárhelyi B, Balog A.

Immunobiology. 2013 Mar;218(3):311-6. doi: 10.1016/j.imbio.2012.05.013. Epub 2012 May 23.

PMID:
22705192
15.

N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3.

Chang SC, Huq R, Chhabra S, Beeton C, Pennington MW, Smith BJ, Norton RS.

FEBS J. 2015 Jun;282(12):2247-59. doi: 10.1111/febs.13294. Epub 2015 Apr 23.

16.

Immunosuppressive evidence of Tityus serrulatus toxins Ts6 and Ts15: insights of a novel K(+) channel pattern in T cells.

Pucca MB, Bertolini TB, Cerni FA, Bordon KC, Peigneur S, Tytgat J, Bonato VL, Arantes EC.

Immunology. 2016 Feb;147(2):240-50. doi: 10.1111/imm.12559.

17.

Selective inhibition of CCR7(-) effector memory T cell activation by a novel peptide targeting Kv1.3 channel in a rat experimental autoimmune encephalomyelitis model.

Li Z, Liu WH, Han S, Peng BW, Yin J, Wu YL, He XH, Li WX.

J Biol Chem. 2012 Aug 24;287(35):29479-94. doi: 10.1074/jbc.M112.379594. Epub 2012 Jul 3.

18.

Targeting effector memory T-cells with Kv1.3 blockers.

Wulff H, Pennington M.

Curr Opin Drug Discov Devel. 2007 Jul;10(4):438-45. Review.

PMID:
17659485
19.

Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis--xenograft model.

Kundu-Raychaudhuri S, Chen YJ, Wulff H, Raychaudhuri SP.

J Autoimmun. 2014 Dec;55:63-72. doi: 10.1016/j.jaut.2014.07.003. Epub 2014 Aug 28.

20.

Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis.

Beeton C, Wulff H, Barbaria J, Clot-Faybesse O, Pennington M, Bernard D, Cahalan MD, Chandy KG, Béraud E.

Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13942-7.

Supplemental Content

Support Center